27.07.2017 • NewsAustraliaAzelisElaine Burridge

Azelis Expands In Australia/New Zealand

The acquisition strengthens Azelis’ presence in the region and positions it...
The acquisition strengthens Azelis’ presence in the region and positions it among the top distributors in the two countries. Australia and New Zealand are wealthy countries, rich in natural resources with growing populations, said Azelis’ CEO, Hans Joachim Müller

Azelis has acquired Chemcolour, a leading supplier of specialty chemicals and food ingredients in Australia and New Zealand, for an undisclosed sum.

The acquisition strengthens Azelis’ presence in the region and positions it among the top distributors in the two countries. Australia and New Zealand are wealthy countries, rich in natural resources with growing populations, said Azelis’ CEO, Hans Joachim Müller, adding that Chemcolour is a great platform to extend agreements with its existing, global principal suppliers.

Chemcolour Australia has a manufacturing plant in Sydney and application and development laboratories in both Sydney and Melbourne. The New Zealand business has its primary manufacturing facility in Auckland with secondary blending facilities in Christchurch. The distributor also performs contract manufacture for several well known companies.

The transaction is expected to complete over the next months. All 90 of Chemcolour’s employees will transfer to Azelis.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.